No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.

  title={No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.},
  author={Robert J. Mairs and Shona H Cunningham and James Russell and Amanda Armour and Jonathan Owens and K McKellar and Mark Nicholas Gaze},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  volume={36 6},
UNLABELLED Iodine-131-metaiodobenzylguanidine ([131I]MIBG) is a radiopharmaceutical for imaging as well as targeted radiotherapy of neuroblastoma. It is predicted that the use of no-carrier-added [131I]MIBG, rather than the conventional low specific activity preparation, will result in an enhanced therapeutic ratio because of different transport processes in neuroblastoma compared with most normal tissues. METHODS The main aims of the study were: (1) to determine whether [131I]MIBG of… CONTINUE READING